Financial Contrast: AEON Biopharma (AEON) vs. Its Peers

AEON Biopharma (NASDAQ:AEON) is one of 1,060 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare AEON Biopharma to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares AEON Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
AEON Biopharma Competitors	-3,590.11%	-276.96%	-39.10%

Volatility & Risk

AEON Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, AEON Biopharma’s rivals have a beta of 3.71, meaning that their average stock price is 271% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AEON Biopharma and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	0	1	0	3.00
AEON Biopharma Competitors	7748	21136	48846	1227	2.55

AEON Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 651.88%. As a group, “Pharmaceutical preparations” companies have a potential upside of 187.67%. Given AEON Biopharma’s stronger consensus rating and higher possible upside, research analysts clearly believe AEON Biopharma is more favorable than its rivals.

Valuation & Earnings

This table compares AEON Biopharma and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
AEON Biopharma	N/A	-$36.63 million	3.69
AEON Biopharma Competitors	$9.59 billion	$147.39 million	-5.35

AEON Biopharma’s rivals have higher revenue and earnings than AEON Biopharma. AEON Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 23.5% of AEON Biopharma shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

AEON Biopharma beats its rivals on 7 of the 13 factors compared.

AEON Biopharma Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.